Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Candel Therapeutics’ SEC disclosures can feel like decoding lab results—pages packed with virology data, trial endpoints and cash-runway tables. If you’ve ever Googled “Candel Therapeutics insider trading Form 4 transactions” or hunted for a Candel Therapeutics quarterly earnings report 10-Q filing, you know how time-consuming EDGAR can be.
Stock Titan resolves that. Our platform streams Candel Therapeutics Form 4 insider transactions real-time and delivers Candel Therapeutics SEC filings explained simply with AI-powered summaries. One click reveals a concise Candel Therapeutics earnings report filing analysis, while side-by-side comparisons make understanding Candel Therapeutics SEC documents with AI straightforward. We cover every form—10-K, 10-Q, 8-K, S-1 and DEF 14A—and tag key data points as soon as they hit EDGAR, complete with real-time alerts.
Why dig deeper? The Candel Therapeutics annual report 10-K simplified highlights R&D spend, clinical milestones for its adenovirus and HSV platforms, and liquidity runway—critical for biotech valuations. Real-time alerts flag Candel Therapeutics executive stock transactions Form 4, while the Candel Therapeutics proxy statement executive compensation breaks down how leadership incentives align with pipeline progress. Need context on sudden announcements? Get the Candel Therapeutics 8-K material events explained within minutes, including links to new trial data and secondary offerings. With AI-powered summaries, real-time updates and focused biotech expertise, you’ll move from raw documents to actionable insight before the market reacts.
Candel Therapeutics filed a Form S-3 shelf registration to offer up to $300,000,000 of securities, including a separate sale-agreement prospectus to sell up to $50,000,000 of common stock under an at-the-market agreement with Jefferies LLC. The prospectus states the company is a clinical-stage developer of off-the-shelf viral immunotherapies. The lead adenovirus candidate, CAN-2409, recently completed a successful Phase 3 trial in localized prostate cancer and produced positive Phase 2a results in non-small cell lung cancer and borderline resectable pancreatic ductal adenocarcinoma. The HSV-based candidate CAN-3110 is in an ongoing investigator-sponsored Phase 1b trial for recurrent high-grade glioma.
The document discloses Nasdaq listing (ticker CADL) with a closing price of $6.35 on August 12, 2025, 54,895,099 shares outstanding as of August 1, 2025, and outstanding Series B warrants (3,672,484 unconditional and up to 3,672,484 conditional). Use of proceeds is described as working capital, R&D, manufacturing, clinical trials and potential acquisitions. The company identifies itself as an emerging growth company and a smaller reporting company and includes corporate governance provisions such as a classified board and broad preferred-stock authorization.
Candel Therapeutics, Inc. (CADL) reported interim results showing material clinical progress and a strengthened balance sheet as of June 30, 2025. Cash and cash equivalents totaled $100.7 million and total assets were $105.97 million. For the six months ended June 30, 2025 the company reported net income of $2.6 million, driven largely by a $20.6 million favorable change in the fair value of a warrant liability, compared with a net loss of $30.5 million in the prior-year period. The company recorded operating expenses of $19.3 million for the six months.
On the clinical front, CAN-2409 achieved a positive phase 3 result in intermediate-to-high-risk localized prostate cancer under an FDA SPA (p=0.0155; HR 0.70), with median DFS not reached vs. 86.1 months for placebo. Management expects to submit a biologics license application in Q4 2026. Additional positive clinical data were reported for CAN-2409 in NSCLC and pancreatic cancer and ongoing CAN-3110 data support repeat-dosing exploration. The filing also discloses an accumulated deficit of $189.6 million, a current term loan balance and the company’s statement that additional financing will be required to fund operations beyond the next 12 months if circumstances change.
Candel Therapeutics (CADL) reported a significant insider purchase by CEO and Director Paul Peter Tak on June 25, 2025. The transaction involved the acquisition of 42,826 shares at $4.67 per share through a registered direct offering, representing a total investment of approximately $200,000.
Following this transaction, Tak's direct beneficial ownership increased to 268,566 shares. The purchase was executed pursuant to a Securities Purchase Agreement dated June 23, 2025, demonstrating insider confidence in the company's prospects.
Key Transaction Details:
- Transaction Type: Direct Purchase (registered offering)
- Share Price: $4.67
- Total Shares Post-Transaction: 268,566
- Filing Date: June 28, 2025
- Transaction Form: Form 4 (Statement of Changes in Beneficial Ownership)
Paul B. Manning, Director of Candel Therapeutics (CADL), reported significant insider transactions on June 25, 2025. Manning acquired 1,070,663 shares at $4.67 per share through a registered direct offering, demonstrating substantial insider investment totaling approximately $5 million.
Following the transaction, Manning's beneficial ownership includes:
- 2,213,069 shares held indirectly through the Paul B. Manning Revocable Trust
- 1,303,752 shares held indirectly through BKB Growth Investments, LLC
- 1,681,000 shares held directly (jointly with spouse)
The total beneficial ownership amounts to 5,197,821 shares, indicating significant insider confidence in the company. The purchase was made pursuant to a Securities Purchase Agreement dated June 23, 2025, suggesting a planned strategic investment in the company's future.
Christopher Martell, Director of Candel Therapeutics (CADL), reported significant insider transactions and holdings on June 28, 2025:
Key Transaction: Acquired 111,349 shares of Common Stock at $4.67 per share on June 25, 2025, through a registered direct offering. These shares are held indirectly through his spouse.
Additional Indirect Holdings:
- 152,000 shares held through GTAM1 2012 LLC (trust where Martell serves as trustee)
- 283,514 shares held through GTAM1 2012 ADV LLC (where Martell serves as manager)
Total beneficial ownership across all indirect holdings amounts to 546,863 shares. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025. Martell disclaims beneficial ownership of trust-held shares except for his pecuniary interest.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
